DNB Carnegie initiated coverage on biotech firm FluoGuide with a fair value range of 20-70 kronor per share. The stock closed at 33 kronor on Friday.
The bank highlighted the commercial potential of FG001, a primary imaging agent designed to illuminate tumor tissue during surgery. The valuation relies on upcoming clinical trial data for brain, head, and neck cancers.
Positive results could improve regulatory approval prospects and increase company value. DNB Carnegie identified FluoGuide as a potential acquisition target within the biotech sector.